{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T10:55:16Z","timestamp":1790592916689,"version":"4.1.0"},"reference-count":32,"publisher":"Walter de Gruyter GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2026-1257_abs_001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The preanalytical stability of activated partial thromboplastin time (aPTT) and anti-factor Xa (anti-Xa) levels is critical for reliable monitoring of therapeutic unfractionated heparin (UFH). However, current recommendations regarding acceptable preanalytical delays are based on limited and heterogeneous evidence. We systematically reviewed the literature on the preanalytical stability of aPTT and anti-Xa levels in patients receiving therapeutic UFH and assessed study quality using the Checklist for Reporting Stability Studies (CRESS), with studies graded from A (best quality) to D (fail).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-1257_abs_002\">\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>A systematic review was conducted according to the PRISMA 2020 guidelines. Studies evaluating the preanalytical stability of aPTT and\/or anti-Xa levels in patients receiving therapeutic UFH were identified through a systematic literature search. Study quality and reporting were assessed using the 20-item CRESS checklist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-1257_abs_003\">\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Nine studies published between 1983 and 2025 met the inclusion criteria. Marked heterogeneity was observed in study design, preanalytical conditions, analytical methods, stability criteria, and statistical analyses. According to the CRESS, seven studies were graded C or D, while only two achieved grade B. Reported stability limits varied widely according to sample type, collection tube (citrate vs. CTAD), analytical reagent, storage conditions, and study methodology. Delayed centrifugation and delayed analysis were consistently associated with decreases in aPTT and anti-Xa levels. CTAD tubes and dextran sulphate-containing anti-Xa assays did not demonstrate a consistent stability advantage. Importantly, studies evaluating patient-level outcomes reported clinically relevant patient reclassification despite apparently acceptable analytical stability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-1257_abs_004\">\n                    <jats:title>Outlook<\/jats:title>\n                    <jats:p>Evidence regarding the preanalytical stability of aPTT and anti-Xa levels remains limited by methodological heterogeneity, inconsistent stability criteria, and incomplete reporting. Based on the available evidence, centrifugation within 1 hour after blood collection followed by prompt analysis should remain the reference approach for therapeutic UFH monitoring. Future stability studies should comply with CRESS recommendations, use standardized acceptability criteria, and incorporate clinically relevant outcomes, including patient reclassification, to establish evidence-based recommendations for UFH monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2026-1257","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:55:41Z","timestamp":1790589341000},"source":"Crossref","is-referenced-by-count":0,"title":["Preanalytical stability of aPTT and anti-Xa levels for therapeutic unfractionated heparin monitoring: a systematic review and critical appraisal using CRESS criteria"],"prefix":"10.1515","author":[{"given":"Annabelle","family":"Dupont","sequence":"first","affiliation":[{"name":"Haemostasis and Transfusion Department , CHU Lille , Lille , France"},{"name":"Inserm U1011, Lille Pasteur Institute , Lille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Gouin-Thibault","sequence":"additional","affiliation":[{"name":"Department of Laboratory Hematology , Rennes University Hospital , Rennes , France"},{"name":"Institute for Research in Health, Environment and Work (INSERM U1085), University of Rennes , Rennes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lecompte","sequence":"additional","affiliation":[{"name":"Department of Laboratory Hematology , Rennes University Hospital , Rennes , France"},{"name":"University of Lorraine , Nancy , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mullier","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Universit\u00e9 Catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), NARILIS , Namur , Belgium"},{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique (IREC),UCLouvain , Namur , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"2026092809553898428_j_cclm-2026-1257_ref_001","doi-asserted-by":"crossref","unstructured":"Hirsh, J, Raschke, R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(3 Suppl):188S\u2013203S. https:\/\/doi.org\/10.1378\/chest.126.3_suppl.188S.","DOI":"10.1378\/chest.126.3_suppl.188S"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_002","doi-asserted-by":"crossref","unstructured":"Gouin-Thibault, I, Mansour, A, Hardy, M, Gu\u00e9ret, P, de Maistre, E, Siguret, V, et al.. Management of therapeutic-intensity unfractionated heparin: a narrative review on critical points. TH Open 2024;8:e297\u2013307. https:\/\/doi.org\/10.1055\/a-2359-0987.","DOI":"10.1055\/a-2359-0987"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_003","unstructured":"Gouin-Thibault, I, Frere, C, Castellucci, LA, Connors, JM, Cuker, A, Levy, JH, et al.. UFH working group. How to monitor and manage unfractionated heparin in practice (Part 1): guidance from the SSC of the ISTH. J\u00a0Thromb Haemost 2026:S1538-7836(26)00336-3."},{"key":"2026092809553898428_j_cclm-2026-1257_ref_004","doi-asserted-by":"crossref","unstructured":"Salazar, E, Higgins, RA. Automation in the thrombosis and hemostasis laboratory. Methods Mol Biol 2023;2663:51\u201362.","DOI":"10.1007\/978-1-0716-3175-1_3"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_005","doi-asserted-by":"crossref","unstructured":"Gosselin, RC, Marlar, RA. Preanalytical variables in coagulation testing: setting the stage for accurate results. Semin Thromb Hemost 2019;45:433\u201348. https:\/\/doi.org\/10.1055\/s-0039-1692700.","DOI":"10.1055\/s-0039-1692700"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_006","doi-asserted-by":"crossref","unstructured":"Denton, J, Lane, DA, Thunberg, L, Slater, AM, Lindahl, U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J 1983;209:455\u201360. https:\/\/doi.org\/10.1042\/bj2090455.","DOI":"10.1042\/bj2090455"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_007","unstructured":"Narayanan, S. Preanalytical aspects of coagulation testing. Haematologica 1995;80(2 Suppl):1\u20136."},{"key":"2026092809553898428_j_cclm-2026-1257_ref_008","unstructured":"CLSI. Collection. Transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays: approved guideline, 5th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. CLSI document H21-A5."},{"key":"2026092809553898428_j_cclm-2026-1257_ref_009","doi-asserted-by":"crossref","unstructured":"Flaujac, C, Delassasseigne, C, Hurtaud-Roux, MF, Delahousse, B, Boissier, E, Desconclois, C, Working Group on Preanalytics in the French Society of Thrombosis Haemostasis. Stability of hemostasis parameters in whole blood, plasma, and frozen plasma: literature review and recommendations of the SFTH (French Society of Thrombosis and Haemostasis). Semin Thromb Hemost 2025;51:524\u201340. https:\/\/doi.org\/10.1055\/s-0044-1788901.","DOI":"10.1055\/s-0044-1788901"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_010","doi-asserted-by":"crossref","unstructured":"Kitchen, S, Adcock, DM, Dauer, R, Kristoffersen, AH, Lippi, G, Mackie, I, et al.. International Ccouncil for Standardisation in Haematology (ICSH) recommendations for collection of blood samples for coagulation testing. Int J Lab Hematol 2021;43:571\u201380. https:\/\/doi.org\/10.1111\/ijlh.13584.","DOI":"10.1111\/ijlh.13584"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_011","doi-asserted-by":"crossref","unstructured":"Cornes, M, Simundic, AM, Cadamuro, J, Costelloe, SJ, Baird, G, Kristensen, GBB, et al.. The CRESS checklist for reporting stability studies: on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) working group for the preanalytical phase (WG-PRE). Clin Chem Lab Med 2020;59:59\u201369. https:\/\/doi.org\/10.1515\/cclm-2020-0061.","DOI":"10.1515\/cclm-2020-0061"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_012","doi-asserted-by":"crossref","unstructured":"Cornes, M, Vermeersch, P, \u0160imundi\u0107, AM, Von Meyer, A, \u0160\u00e1lek, T, Meyer, B, et al.. The final part of the CRESS trilogy\u00a0\u2013\u00a0how to evaluate the quality of stability studies. Clin Chem Lab Med 2024;62:2128\u201339. https:\/\/doi.org\/10.1515\/cclm-2024-0527.","DOI":"10.1515\/cclm-2024-0527"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_013","doi-asserted-by":"crossref","unstructured":"Page, MJ, McKenzie, JE, Bossuyt, PM, Boutron, I, Hoffmann, TC, Mulrow, CD, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_014","doi-asserted-by":"crossref","unstructured":"Contant, G, Gouault-Heilmann, M, Martinoli, JL. Heparin inactivation during blood storage: its prevention by blood collection in citric acid, theophylline, adenosine, dipyridamole-C.T.A.D. mixture. Thromb Res 1983;31:365\u201374. https:\/\/doi.org\/10.1016\/0049-3848(83)90337-7.","DOI":"10.1016\/0049-3848(83)90337-7"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_015","doi-asserted-by":"crossref","unstructured":"van den Besselaar, AM, Meeuwisse-Braun, J, Jansen-Gr\u00fcter, R, Bertina, RM. Monitoring heparin therapy by the activated partial thromboplastin time-the effect of pre-analytical conditions. Thromb Haemost 1987;57:226\u201331. https:\/\/doi.org\/10.1055\/s-0038-1651099.","DOI":"10.1055\/s-0038-1651099"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_016","doi-asserted-by":"crossref","unstructured":"Adcock, D, Kressin, D, Marlar, RA. The effect of time and temperature variables on routine coagulation tests. Blood Coagul Fibrinolysis 1998;9:463\u201370. https:\/\/doi.org\/10.1097\/00001721-199809000-00002.","DOI":"10.1097\/00001721-199809000-00002"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_017","doi-asserted-by":"crossref","unstructured":"Heil, W, Grunewald, R, Amend, M, Heins, M. Influence of time and temperature on coagulation analytes in stored plasma. Clin Chem Lab Med 1998;36:459\u201362. https:\/\/doi.org\/10.1515\/cclm.1998.077.","DOI":"10.1515\/CCLM.1998.077"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_018","doi-asserted-by":"crossref","unstructured":"Awad, MA, Eldeen, OA, Ibrahim, HA. Stability of activated partial thromboplastin time (APTT) test under different storage conditions. Hematology 2006;11:311\u20135. https:\/\/doi.org\/10.1080\/10245330500397752.","DOI":"10.1080\/10245330500397752"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_019","doi-asserted-by":"crossref","unstructured":"Ray, M. Stability of the activated partial thromboplastin time used to monitor unfractionated heparin. J\u00a0Thromb Haemost 2008;6:1817\u20139. https:\/\/doi.org\/10.1111\/j.1538-7836.2008.03101.x.","DOI":"10.1111\/j.1538-7836.2008.03101.x"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_020","doi-asserted-by":"crossref","unstructured":"Billoir, P, Clavier, T, Guilbert, A, Barbay, V, Chr\u00e9tien, MH, Fresel, M, et al.. Is citrate theophylline adenosine dipyridamole (CTAD) better than citrate to survey unfractionated heparin treatment? Has delayed centrifugation a real impact on this survey? J\u00a0Thromb Thrombolysis 2019;48:277\u201383. https:\/\/doi.org\/10.1007\/s11239-019-01882-1.","DOI":"10.1007\/s11239-019-01882-1"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_021","doi-asserted-by":"crossref","unstructured":"Toulon, P, Appert-Flory, A, Fischer, F, Buvat, S, Jambou, D, Mahagne, MH. Monitoring unfractionated heparin therapy. 4\u00a0hour-stability of anti-Xa activity in unspun citrated tubes. Thromb Res 2020;186:7\u201312. https:\/\/doi.org\/10.1016\/j.thromres.2019.10.019.","DOI":"10.1016\/j.thromres.2019.10.019"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_022","doi-asserted-by":"crossref","unstructured":"Gremillet, M, Talon, L, Lebreton, A, Sinegre, T. Monitoring heparin therapy: stability of two different anti-Xa assays using blood samples collected in citrate-containing and CTAD tubes. Thromb J 2023;21:21. https:\/\/doi.org\/10.1186\/s12959-023-00465-8.","DOI":"10.1186\/s12959-023-00465-8"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_023","doi-asserted-by":"crossref","unstructured":"Sandberg, S, Fraser, CG, Horvath, AR, Jansen, R, Jones, G, Oosterhuis, W, et al.. Defining analytical performance specifications: consensus statement from the 1st strategic conference of the European Federation of clinical chemistry and laboratory medicine. Clin Chem Lab Med 2015;53:833\u20135. https:\/\/doi.org\/10.1515\/cclm-2015-0067.","DOI":"10.1515\/cclm-2015-0067"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_024","doi-asserted-by":"crossref","unstructured":"Fraser, CG. Reference change values. Clin Chem Lab Med 2011;50:807\u201312. https:\/\/doi.org\/10.1515\/cclm.2011.733.","DOI":"10.1515\/cclm.2011.733"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_025","doi-asserted-by":"crossref","unstructured":"Favaloro, EJ, Arunachalam, S, Pasalic, L. External quality assessment for unfractionated heparin monitoring: an update from Australasia\/Asia-Pacific. Semin Thromb Hemost 2026. https:\/\/doi.org\/10.1055\/a-2779-0035. in press.","DOI":"10.1055\/a-2900-7026"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_026","doi-asserted-by":"crossref","unstructured":"Favaloro, EJ, Reardon, B, Pasalic, L. Laboratory monitoring and measuring of clinical anticoagulants. Semin Thromb Hemost 2026. https:\/\/doi.org\/10.1055\/a-2907-8841. in press.","DOI":"10.1055\/a-2907-8841"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_027","doi-asserted-by":"crossref","unstructured":"Hardy, M, Cabo, J, Deli\u00e8ge, A, Douxfils, J, Gouin-Thibault, I, Lecompte, T, et al.. Reassessment of dextran sulfate in anti-Xa assay for unfractionated heparin laboratory monitoring. Res Pract Thromb Haemost 2023;7:102257. https:\/\/doi.org\/10.1016\/j.rpth.2023.102257.","DOI":"10.1016\/j.rpth.2023.102257"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_028","doi-asserted-by":"crossref","unstructured":"Savard, P, Curis, E, Gouin-Thibault, I, Toussaint-Hacquard, M, Delassasseigne, C, Bauters, A, et al.. Laboratory monitoring of UFH in different settings (DEXHEP study): association between Anti-Xa levels, platelet factor 4 (PF4) plasma levels and dextran sulfate. Thromb Haemost 2025. https:\/\/doi.org\/10.1055\/a-2749-6046.","DOI":"10.1055\/a-2749-6046"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_029","doi-asserted-by":"crossref","unstructured":"van Balveren, JA, Huijskens, MJ, Gemen, EF, P\u00e9qu\u00e9riaux, NC, Kusters, R. Effects of time and temperature on 48 routine chemistry, haematology and coagulation analytes in whole blood samples. Ann Clin Biochem 2017;54:448\u201362. https:\/\/doi.org\/10.1177\/0004563216665868.","DOI":"10.1177\/0004563216665868"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_030","doi-asserted-by":"crossref","unstructured":"Kim, H, Kim, Y, Lee, HK. Influence of preanalytical variables on prothrombin time, activated partial thromboplastin time, and fibrinogen. Clin Lab 2015;61:1337\u201340. https:\/\/doi.org\/10.7754\/clin.lab.2015.150231.","DOI":"10.7754\/Clin.Lab.2015.150231"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_031","doi-asserted-by":"crossref","unstructured":"Oddoze, C, Lombard, E, Portugal, H. Stability study of 81 analytes in human whole blood, in serum and in plasma. Clin Biochem 2012;45:464\u20139. https:\/\/doi.org\/10.1016\/j.clinbiochem.2012.01.012.","DOI":"10.1016\/j.clinbiochem.2012.01.012"},{"key":"2026092809553898428_j_cclm-2026-1257_ref_032","doi-asserted-by":"crossref","unstructured":"Salvagno, GL, Lippi, G, Montagnana, M, Franchini, M, Poli, G, Guidi, GC. Influence of temperature and time before centrifugation of specimens for routine coagulation testing. Int J Lab Hematol 2009;31:462\u20137. https:\/\/doi.org\/10.1111\/j.1751-553x.2008.01058.x.","DOI":"10.1111\/j.1751-553X.2008.01058.x"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-1257\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-1257\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:55:50Z","timestamp":1790589350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-1257\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":32,"alternative-id":["10.1515\/cclm-2026-1257"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2026-1257","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]}}}